《肝细胞癌合并门静脉癌栓多学科诊治中国专家共识（2018年版）》
Chinese Expert Consensus on Multidisciplinary Diagnosis and Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus (2018 Edition).
作者信息
Cheng Shuqun, Chen Minshan, Cai Jianqiang, Sun Juxian, Guo Rongping, Bi Xinyu, Lau Wan Yee, Wu Mengchao
机构信息
aDepartment of Hepatic Surgery VI, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China.
bDepartment of Hepatobiliary Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China.
出版信息
Liver Cancer. 2020 Jan;9(1):28-40. doi: 10.1159/000503685. Epub 2019 Nov 6.
Abstract
Portal vein tumor thrombus (PVTT) is very common, and it plays a major role in the prognosis and clinical staging of hepatocellular carcinoma (HCC). We have published the first version of the Consensus in 2016. Over the past several years, many new evidences for the treatment of PVTT become available especially for the advent of new targeted drugs which have further improved the prognosis of PVTT. So, the Chinese Association of Liver Cancer revised the 2016 version of consensus to adapt to the development of PVTT treatment. Future treatment strategies for HCC with PVTT in China would depend on new evidences from more future clinical trials.
摘要
门静脉癌栓（PVTT）非常常见，并且在肝细胞癌（HCC）的预后和临床分期中起主要作用。我们于2016年发布了第一版《共识》。在过去的几年里，出现了许多关于PVTT治疗的新证据，尤其是新靶向药物的问世，这进一步改善了PVTT的预后。因此，中国肝癌协会对2016版《共识》进行了修订，以适应PVTT治疗的发展。中国未来针对伴有PVTT的HCC的治疗策略将取决于更多未来临床试验的新证据。
相似文献
1
Chinese Expert Consensus on Multidisciplinary Diagnosis and Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus (2018 Edition).《肝细胞癌合并门静脉癌栓多学科诊治中国专家共识（2018年版）》
Liver Cancer. 2020 Jan;9(1):28-40. doi: 10.1159/000503685. Epub 2019 Nov 6.
2
Guidelines for Diagnosis and Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus in China (2021 Edition).中国肝细胞癌合并门静脉癌栓诊断和治疗多学科专家共识（2021年版）
Liver Cancer. 2022 Mar 17;11(4):315-328. doi: 10.1159/000523997. eCollection 2022 Jul.
3
Chinese expert consensus on multidisciplinary diagnosis and treatment of hepatocellular carcinoma with portal vein tumor thrombus: 2016 edition.《肝细胞癌合并门静脉癌栓多学科诊治中国专家共识（2016年版）》
Oncotarget. 2017 Jan 31;8(5):8867-8876. doi: 10.18632/oncotarget.12817.
4
Surgical resection for hepatocellular carcinoma with portal vein tumor thrombus in the Asia-Pacific region beyond the Barcelona Clinic Liver Cancer treatment algorithms: a review and update.亚太地区超出巴塞罗那临床肝癌治疗方案的伴门静脉癌栓肝细胞癌的手术切除：综述与更新
Oncotarget. 2017 Jun 27;8(54):93258-93278. doi: 10.18632/oncotarget.18735. eCollection 2017 Nov 3.
5
An Eastern Hepatobiliary Surgery Hospital/Portal Vein Tumor Thrombus Scoring System as an Aid to Decision Making on Hepatectomy for Hepatocellular Carcinoma Patients With Portal Vein Tumor Thrombus: A Multicenter Study.东方肝胆外科医院/门静脉癌栓评分系统辅助肝癌合并门静脉癌栓患者行肝切除术的决策：一项多中心研究。
Hepatology. 2019 May;69(5):2076-2090. doi: 10.1002/hep.30490. Epub 2019 Mar 12.
6
The strategies for treating primary hepatocellular carcinoma with portal vein tumor thrombus.原发性肝癌合并门静脉癌栓的治疗策略。
Int J Surg. 2015 Aug;20:8-16. doi: 10.1016/j.ijsu.2015.05.009. Epub 2015 May 27.
7
Portal vein tumor thrombus in advanced hepatocellular carcinoma: A case report.晚期肝细胞癌门静脉瘤栓：一例报告。
Oncol Lett. 2015 Jun;9(6):2495-2498. doi: 10.3892/ol.2015.3115. Epub 2015 Apr 14.
8
Challenging the Treatment Paradigm: Selecting Patients for Surgical Management of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus.挑战治疗模式：选择肝细胞癌伴门静脉癌栓手术治疗的患者
J Hepatocell Carcinoma. 2021 Jul 28;8:851-860. doi: 10.2147/JHC.S291530. eCollection 2021.
9
Development of a prognostic score to predict response to Yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion.开发一种预后评分，以预测伴有门静脉侵犯的肝细胞癌对钇-90 放射性栓塞治疗的反应。
J Hepatol. 2018 Apr;68(4):724-732. doi: 10.1016/j.jhep.2017.12.026. Epub 2018 Jan 10.
10
[Percutaneous laser ablation in the treatment of portal vein tumor thrombus in 93 hepatocellular carcinoma patients].[经皮激光消融治疗93例肝细胞癌门静脉癌栓]
Zhonghua Zhong Liu Za Zhi. 2007 Jun;29(6):449-52.
引用本文的文献
1
Hepatic arterial infusion chemotherapy plus lenvatinib and PD-1 inhibitors versus lenvatinib plus PD-1 inhibitors as first-line treatment for hepatocellular carcinoma with high tumour burden and portal vein tumour thrombus (CHANCE 2416): study protocol of a multicentre, retrospective, target trial emulation design.肝动脉灌注化疗联合乐伐替尼及PD-1抑制剂与乐伐替尼联合PD-1抑制剂作为高肿瘤负荷和门静脉癌栓肝细胞癌一线治疗的比较（CHANCE 2416）：一项多中心、回顾性、目标试验模拟设计的研究方案
BMJ Open. 2025 Sep 9;15(9):e099510. doi: 10.1136/bmjopen-2025-099510.
2
Locoregional Therapies for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus.伴有门静脉癌栓的肝细胞癌的局部区域治疗
J Gastrointest Cancer. 2025 Jul 23;56(1):162. doi: 10.1007/s12029-025-01280-2.
3
Combining Hepatic Arterial Interventional Therapies with Lenvatinib and Programmed Cell Death-1 Inhibitors for Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: A Single-Center, Real-World Study.肝动脉介入治疗联合乐伐替尼和程序性细胞死亡蛋白1抑制剂治疗伴门静脉癌栓的肝细胞癌：一项单中心真实世界研究
J Hepatocell Carcinoma. 2025 Jul 2;12:1267-1278. doi: 10.2147/JHC.S530550. eCollection 2025.
4
Clinical Outcomes of Hepatic Arterial Infusion Chemotherapy Plus Lenvatinib and Tislelizumab for Treating Hepatocellular Carcinoma and Type IV Portal Vein Tumor Thrombus.肝动脉灌注化疗联合仑伐替尼和替雷利珠单抗治疗肝细胞癌合并IV型门静脉癌栓的临床疗效
J Hepatocell Carcinoma. 2025 Jan 25;12:169-182. doi: 10.2147/JHC.S488734. eCollection 2025.
5
WTAP regulates Mitochondrial damage and Lipid oxidation in HCC by NOA1 mediated m6A modification.WTAP通过NOA1介导的m6A修饰调节肝癌中的线粒体损伤和脂质氧化。
J Cancer. 2025 Jan 1;16(1):315-330. doi: 10.7150/jca.102618. eCollection 2025.
6
Single-cell and bulk transcriptomic datasets enable the development of prognostic models based on dynamic changes in the tumor immune microenvironment in patients with hepatocellular carcinoma and portal vein tumor thrombus.单细胞和批量转录组数据集使基于肝癌和门静脉癌栓患者肿瘤免疫微环境动态变化的预后模型的开发成为可能。
Front Immunol. 2024 Oct 28;15:1414121. doi: 10.3389/fimmu.2024.1414121. eCollection 2024.
7
Radiotherapy plus lenvatinib versus radiotherapy plus sorafenib for hepatocellular carcinoma with portal vein tumor thrombus: a retrospective study.放射治疗联合乐伐替尼与放射治疗联合索拉非尼治疗伴门静脉癌栓的肝细胞癌：一项回顾性研究
Front Pharmacol. 2024 Oct 15;15:1458819. doi: 10.3389/fphar.2024.1458819. eCollection 2024.
8
Perioperative Tislelizumab plus intensity modulated radiotherapy in resectable hepatocellular carcinoma with macrovascular invasion: a phase II trial.可切除伴大血管侵犯肝细胞癌的围手术期替雷利珠单抗联合调强放疗：一项Ⅱ期临床试验。
Nat Commun. 2024 Oct 29;15(1):9350. doi: 10.1038/s41467-024-53704-5.
9
Stereotactic body radiotherapy versus lenvatinib for hepatocellular carcinoma with portal vein tumor thrombosis: a propensity matching score analysis.立体定向体部放疗与仑伐替尼治疗合并门静脉癌栓的肝细胞癌：倾向评分匹配分析。
Radiat Oncol. 2024 Oct 11;19(1):143. doi: 10.1186/s13014-024-02527-1.
10
Is DEB-TACE as locoregional therapy before liver transplantation for hepatocellular carcinoma effective?DEB-TACE 作为肝癌肝移植前的局部区域治疗是否有效？
BMC Gastroenterol. 2024 Oct 3;24(1):348. doi: 10.1186/s12876-024-03434-1.
本文引用的文献
1
A Phase II and Biomarker Study of Sorafenib Combined with Modified FOLFOX in Patients with Advanced Hepatocellular Carcinoma.索拉非尼联合改良 FOLFOX 方案治疗晚期肝细胞癌的 II 期及生物标志物研究。
Clin Cancer Res. 2019 Jan 1;25(1):80-89. doi: 10.1158/1078-0432.CCR-18-0847. Epub 2018 Sep 6.
2
Significance of hepatic resection and adjuvant hepatic arterial infusion chemotherapy for hepatocellular carcinoma with portal vein tumor thrombus in the first branch of portal vein and the main portal trunk: a project study for hepatic surgery of the Japanese Society of Hepato-Biliary-Pancreatic Surgery.对于第一肝门部和主门静脉分支的肝癌合并门静脉癌栓，肝切除术和辅助性肝动脉灌注化疗的意义：日本肝胆胰外科学会肝脏外科研讨会项目研究。
J Hepatobiliary Pancreat Sci. 2018 Sep;25(9):395-402. doi: 10.1002/jhbp.574. Epub 2018 Sep 4.
3
Treatment of Naïve HCC Combined with Segmental or Subsegmental Portal Vein Tumor Thrombosis: Liver Resection TACE Followed by Radiotherapy.初治肝细胞癌合并节段性或亚节段性门静脉肿瘤血栓形成的治疗：肝切除、经动脉化疗栓塞后放疗
Anticancer Res. 2018 Aug;38(8):4919-4925. doi: 10.21873/anticanres.12808.
4
A systematic review comparing outcomes of surgical resection and non-surgical treatments for patients with hepatocellular carcinoma and portal vein tumor thrombus.系统回顾比较手术切除和非手术治疗肝细胞癌合并门静脉癌栓患者的结局。
HPB (Oxford). 2018 Dec;20(12):1119-1129. doi: 10.1016/j.hpb.2018.06.1804. Epub 2018 Jul 25.
5
Randomized, prospective, comparative study on the effects and safety of sorafenib vs. hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis.随机、前瞻性、比较研究索拉非尼与肝动脉灌注化疗治疗伴有门静脉癌栓的晚期肝细胞癌的疗效和安全性。
Cancer Chemother Pharmacol. 2018 Sep;82(3):469-478. doi: 10.1007/s00280-018-3638-0. Epub 2018 Jul 7.
6
Should transarterial chemoembolization be given before or after intensity-modulated radiotherapy to treat patients with hepatocellular carcinoma with portal vein tumor thrombus? a propensity score matching study.对于伴有门静脉癌栓的肝细胞癌患者，经动脉化疗栓塞应在调强放疗之前还是之后进行？一项倾向评分匹配研究。
Oncotarget. 2018 May 11;9(36):24537-24547. doi: 10.18632/oncotarget.25224.
7
Effect of Huaier granule on recurrence after curative resection of HCC: a multicentre, randomised clinical trial.槐耳颗粒对肝癌根治性切除术后复发的影响：一项多中心、随机临床试验。
Gut. 2018 Nov;67(11):2006-2016. doi: 10.1136/gutjnl-2018-315983. Epub 2018 May 25.
8
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma.欧洲肝脏研究学会临床实践指南：肝细胞癌的管理
J Hepatol. 2018 Jul;69(1):182-236. doi: 10.1016/j.jhep.2018.03.019. Epub 2018 Apr 5.
9
Efficacy and Safety of Transarterial Chemoembolization Plus External Beam Radiotherapy vs Sorafenib in Hepatocellular Carcinoma With Macroscopic Vascular Invasion: A Randomized Clinical Trial.经动脉化疗栓塞联合外照射放疗与索拉非尼治疗伴有宏观血管侵犯的肝细胞癌的疗效和安全性：一项随机临床试验。
JAMA Oncol. 2018 May 1;4(5):661-669. doi: 10.1001/jamaoncol.2017.5847.
10
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.奥沙利铂联合氟尿嘧啶/亚叶酸肝动脉灌注化疗对比索拉非尼治疗晚期肝细胞癌
J Hepatol. 2018 Jul;69(1):60-69. doi: 10.1016/j.jhep.2018.02.008. Epub 2018 Feb 20.
Zotero 插件